Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that on February 28, 2017 it resubmitted its NDA (New Drug Application) for RhopressaTM to the FDA after notification by its contract drug product manufacturer that the vendor’s Tampa, Florida facility is now ready for